These findings suggest that modulators of CB2 have subtle pharmacological complexities, and understanding these differences may provide insight into developing better treatments for brain disorders such as schizophrenia, pain, and Alzheimer’s disease. This evidence concerns the gene CNR2 and early-onset autosomal dominant Alzheimer disease.